Literature DB >> 17591893

Downregulation of endotoxin-induced uveitis by intravitreal injection of vasoactive intestinal Peptide encapsulated in liposomes.

Laure Lajavardi1, Amélie Bochot, Serge Camelo, Brigitte Goldenberg, Marie-Christine Naud, Francine Behar-Cohen, Elias Fattal, Yvonne de Kozak.   

Abstract

PURPOSE: To reestablish the immunosuppressive microenvironment of the eye, disrupted by ocular inflammation during endotoxin-induced uveitis (EIU), by means of intravitreal injection of vasoactive intestinal peptide (VIP) in saline or encapsulated in liposomes, to increase its bioavailability and efficiency.
METHODS: EIU was induced in Lewis rats by subcutaneous injection of lipopolysaccharide (LPS). Simultaneously, animals were intravitreally injected with saline, saline/VIP, VIP-loaded liposomes (VIP-Lip), or unloaded liposomes. EIU severity and cellular infiltration were assessed by clinical examination and specific immunostaining. VIP concentration was determined in ocular fluids by ELISA. Ocular expression of inflammatory cytokine and chemokine mRNAs was detected by semiquantitative RT-PCR. Biodistribution of rhodamine-conjugated liposomes (Rh-Lip) was analyzed by immunohistochemistry in eyes and regional cervical lymph nodes (LNs).
RESULTS: Twenty-four hours after intravitreal injection of VIP-Lip, VIP concentration in ocular fluids was 15 times higher than after saline/VIP injection. At that time, EIU clinical severity, ocular infiltrating polymorphonuclear leukocytes (PMNs), and, to a lesser extent, ED1(+) macrophages, as well as inflammatory cytokine and chemokine mRNA expression, were significantly reduced in VIP-Lip-injected rats compared with rats injected with saline/VIP, unloaded liposomes, or saline. Rh-Lip was distributed in vitreous, ciliary body, conjunctiva, retina, and sclera. It was internalized by macrophages and PMNs, and VIP colocalized with liposomes at least up to 14 days after injection. In cervical LNs, resident macrophages internalized VIP-Rh-Lip, and some adjacent lymphocytes showed VIP expression.
CONCLUSIONS: VIP was efficient at reducing EIU only when formulated in liposomes, which enhanced its immunosuppressive effect and controlled its delivery to all tissues affected by or involved in ocular inflammation.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17591893     DOI: 10.1167/iovs.06-1305

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  23 in total

Review 1.  Nanocarriers of nanotechnology in retinal diseases.

Authors:  Ali M Al-Halafi
Journal:  Saudi J Ophthalmol       Date:  2014-03-05

2.  Dendrimers for Ocular Drug Delivery.

Authors:  Michael G Lancina; Hu Yang
Journal:  Can J Chem       Date:  2017-05-11       Impact factor: 1.118

3.  Gene therapy with the caspase activation and recruitment domain reduces the ocular inflammatory response.

Authors:  Cristhian J Ildefonso; Henrique Jaime; Manas R Biswal; Shannon E Boye; Qiuhong Li; William W Hauswirth; Alfred S Lewin
Journal:  Mol Ther       Date:  2015-02-20       Impact factor: 11.454

4.  Ocular drug delivery systems: An overview.

Authors:  Ashaben Patel; Kishore Cholkar; Vibhuti Agrahari; Ashim K Mitra
Journal:  World J Pharmacol       Date:  2013

Review 5.  Recent perspectives on the delivery of biologics to back of the eye.

Authors:  Mary Joseph; Hoang M Trinh; Kishore Cholkar; Dhananjay Pal; Ashim K Mitra
Journal:  Expert Opin Drug Deliv       Date:  2016-09-06       Impact factor: 6.648

6.  The expression of cytokines in the aqueous humor and serum during endotoxin-induced uveitis in C3H/HeN mice.

Authors:  Yingzhi Xu; Wei Chen; Hong Lu; Xiaofeng Hu; Shang Li; Jing Wang; Li Zhao
Journal:  Mol Vis       Date:  2010-08-21       Impact factor: 2.367

7.  Expression of TLR4-MyD88 and NF-κB in the iris during endotoxin-induced uveitis.

Authors:  Shang Li; Hong Lu; Xiaofeng Hu; Wei Chen; Yingzhi Xu; Jing Wang
Journal:  Mediators Inflamm       Date:  2010-08-03       Impact factor: 4.711

Review 8.  Targeted drug-delivery approaches by nanoparticulate carriers in the therapy of inflammatory diseases.

Authors:  Wiebke Ulbrich; Alf Lamprecht
Journal:  J R Soc Interface       Date:  2009-11-25       Impact factor: 4.118

Review 9.  Recent perspectives in ocular drug delivery.

Authors:  Ripal Gaudana; J Jwala; Sai H S Boddu; Ashim K Mitra
Journal:  Pharm Res       Date:  2008-08-29       Impact factor: 4.200

10.  Expression of toll-like receptor 4 in uvea-resident tissue macrophages during endotoxin-induced uveitis.

Authors:  Wei Chen; Xiaofeng Hu; Li Zhao; Shang Li; Hong Lu
Journal:  Mol Vis       Date:  2009-03-30       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.